Skip to main content
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. — Investor Relations & Filings

Ticker · TYRA ISIN · US90240B1061 US Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2021-09-09 Capital/Financing Update
Country US United States of America
Listing US TYRA

About Tyra Biosciences, Inc.

https://tyra.bio/

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company specializes in therapies targeting fibroblast growth factor receptor (FGFR) biology, aiming to overcome tumor resistance and address key drivers of disease. Utilizing its proprietary SNÅP Discovery Engine, Tyra Biosciences designs innovative molecular structures. Its lead clinical program involves the development of oral dabogratinib for the treatment of skeletal dysplasia and urologic cancers.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC by Tyra Biosciences, Inc. It is a regulatory filing related to the company's initial public offering (IPO), containing detailed information about the company, its business, financial data, risk factors, management, and offering details. The Form S-1 is a registration statement used for securities offerings under the Securities Act of 1933. This document is not an annual report, earnings release, or any other financial report but a registration statement for capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP), which includes updates on company fundraising and financing activities.
2021-09-09 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter addressed to the SEC regarding a Registration Statement on Form S-1 for Tyra Biosciences, Inc. It discusses confidential treatment requests, valuation methodologies for common stock, stock option grants, and related financial details. The presence of the Form S-1 registration statement and the focus on pricing and valuation for an IPO indicates this is related to a capital raising event. The document is not a full financial report like an Annual Report or Interim Report, nor is it a transcript, audit report, or management report. It is a regulatory filing related to the registration and offering of securities, specifically a confidential treatment request and supplemental information for a Form S-1 registration statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other categories and includes registration statements and related correspondence.
2021-08-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC regarding an Amendment No. 1 to a Draft Registration Statement on Form S-1 for Tyra Biosciences, Inc. It discusses responses to SEC staff comments on the confidential draft amended Registration Statement and mentions the public filing of the Registration Statement on Form S-1. The document is a correspondence related to a registration statement filing, not the registration statement itself or a financial report. It is a regulatory communication addressing SEC comments and amendments to a draft filing. The document length is 4496 characters, which is relatively short and consistent with a regulatory filing or comment letter rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-08-20 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities for sale to the public. It includes detailed information about the company, its business, financial data, risk factors, management, and the offering itself. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of report but a registration statement for securities offering under the Securities Act of 1933. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, so it is not RPA or RNS.
2021-08-20 English
Regulatory Filings 2021
Regulatory Filings
2021-07-13 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Tyra Biosciences, Inc. to the SEC staff comments on a confidential draft Registration Statement on Form S-1. It discusses revisions to the Registration Statement, including pipeline tables, investor disclosures, market data, management biographies, and clinical development plans. The document is not the Registration Statement itself but a comment letter addressing SEC review comments on the draft S-1 filing. It is a regulatory correspondence related to a registration statement for an IPO, not a financial report, earnings release, or other specific report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other categories. The document length (11,261 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or certification.
2021-07-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.